Tests behavioral activation for depression and anxiety in people with colon cancer
Tests brief behavioral activation therapy in colon cancer patients with depression or anxiety.
Plain-language title generated from the registry record
Registry title: Impact of Behavioral Activation on Depression and Quality of Life in Patients with Colon Cancer
Key facts
- Where
- Västerås, SwedenSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults newly diagnosed with colon cancer in Region Västmanland. A short talking therapy called Behavioural Activation is tested for anxiety and depression.
- Sex
- Everyone can join, men and women.
- Disease stage
- Newly diagnosed colon cancer. For the therapy part, also anxiety and/or depression.
- Earlier treatment
- People who started antidepressant treatment within the last month, or who are in psychological treatment now, cannot join.
Main reasons for not taking part
- Language difficulties that make it impossible to take in the treatment
- Ongoing alcohol or substance use syndrome
- Raised suicide risk
- Ongoing psychotic disorder or severe depression
- Ongoing or past manic episode, or cognitive illness or dementia
Read by machine on 9 November 2026.
Where in Sweden
- Centre for Clinical research and Dept. of SurgeryVästerås, SwedenNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Region Västmanland
- Trial code
- NCT06745700
- Record updated
- 20 December 2024
- Original description
The purpose of this randomized clinical trial is to study anxiety and depression symptoms at diagnosis in patients with colon cancer. Previous studies have shown that so-called. Behavioural activation as therapy for these symptoms has a positive impact on the patient's well-being, but it has not been studied whether it also has a positive impact on the patient's mental health in cancer, and whether it can have a prognostically beneficial effect on cancer recurrence risk and survival.Read full original descriptionShow less
Impact of Behavioral Activation on Depression, Anxiety, Health-related Quality of Life (HRQoL), Cancer Recurrence and Survival in Patients with Colon Cancer
The purpose of this randomized clinical trial is to study anxiety and depression symptoms at diagnosis in patients with colon cancer. Previous studies have shown that so-called. Behavioural activation as therapy for these symptoms has a positive impact on the patient's well-being, but it has not been studied whether it also has a positive impact on the patient's mental health in cancer, and whether it can have a prognostically beneficial effect on cancer recurrence risk and survival.
The investigators will investigate the prevalence of anxiety and depression symptoms as well as quality of life in colon cancer patients at diagnosis and at follow-up using self-estimated validated protocols in a prospective cohort study. Data will be compared with data from a reference population. In the cohort study the investigators will also perform a nested randomized clinical trial of a brief psychological treatment called Behavioural Activation to patients with colon cancer and comorbid anxiety and/or depression.
All participants will answer the questionnaires at diagnosis, after1, 2 and 6 months and after 1 and 3 years.
Inclusion: All patients diagnosed with colon cancer in Region Västmanland, will be considered for inclusion. Those who meet the inclusion criteria will be offered to participate in the studies after written approval.
Exclusion: ongoing or previous manic episode; ongoing alcohol or substance use syndrome; ongoing psychotic disorder, severe depression; cognitive illness/dementia; language difficulties that cause patients to be unable to absorb the treatment; elevated suicide risk; antidepressant treatment initiated within the last month; ongoing psychological treatment.